Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhibitor Formation Risk Switching to Kogenate-FS in Severe Hemophilia A
NCT00621673Phase 4Terminated
- Sponsor
- Bayer
- Start
- May 2006
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of octocog alfa in hemophilia A, sponsored by Bayer. Primary endpoint: Risk of Inhibitor Formation at 6 months. Started May 2006; status: terminated.
02
Drugs
octocog alfa
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT00621673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00621673.